Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DTRMWXHS 12

Drug Profile

DTRMWXHS 12

Alternative Names: DTRM-12; DTRMWXHS12

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang DTRM Biopharma
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • No development reported B-cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for phase-I development in Mantle-cell-lymphoma(Second-line therapy or greater) in China (PO, Capsule)
  • 17 Nov 2021 Zhejiang DTRM Biopharma completes a phase I/II trial in Mantle-cell lymphoma (In adults, Refractory metastatic disease, Recurrent) in China (PO) (NCT03836768)
  • 05 Dec 2020 Additional safety and efficacy data from a phase I trial in Diffuse large B-cell lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top